Servier, China's SIMM To Collaborate On Lucitanib Cancer Drug
This article was originally published in PharmAsia News
Executive Summary
Servier and the Shanghai Institute of Materia Medica have signed an agreement to co-develop and market the antitumor drug lucitanib in China.